发明名称 Tolerogenic populations of dendritic cells
摘要 Tolerogenic populations of dendritic cells are provided, where the dendritic cells are characterized by expression of select tissue-specific homing receptors including the chemokine receptors CCR9; or CMKLR1; or the integrin CD103. The dendritic cells may be conventional/myeloid or plasmacytoid dendritic cells. The cells may be isolated from lymphoid tissue, from blood, or from in vitro culture, e.g. bone marrow culture, etc. Methods are provided for their identification, isolation and targeting in immunotherapeutic interventions in suppressing inflammatory disorders including autoimmunity, transplantation responses and allergic diseases. In some embodiments dendritic cell populations are fixed to render them immunosuppressive, thus allowing the cells to be typed and banked for future use.
申请公布号 US8889124(B2) 申请公布日期 2014.11.18
申请号 US200912566454 申请日期 2009.09.24
申请人 The Board of Trustees of the Leland Stanford Junior University 发明人 Hadeiba Husein;Butcher Eugene C.
分类号 A01N63/00;A01N1/02;C12N5/071;C12N5/0784;A61K35/12;A61K39/00 主分类号 A01N63/00
代理机构 Bozicevic, Field & Francis LLP 代理人 Bozicevic, Field & Francis LLP ;Sherwood Pamela J.
主权项 1. A method of decreasing the immune response in a human host to an antigen of interest, the method comprising: combining antibodies that specifically recognize CCR9, antibodies that recognize CD11c, and antibodies that recognize CD123 with a sample comprising human plasmacytoid dendritic cells; selecting for those cells that are positive for expression of CCR9 and are CD11c− CD123+, to provide a tolerogenic dendritic cell population; pulsing the tolerogenic dendritic cells with an antigen of interest; administering the tolerogenic dendritic cell population in a dose effective to substantially decrease the immune response to the antigen of interest.
地址 Palo Alto CA US